Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.

Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

“…102 By intent-to-treat, the 2-year EFS, PFS, and OS rates were 80%, 84%, and 93%, respectively. 102 Other regimens have been used as front-line chemotherapy in elderly patients with HL, including CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) 103 ; brentuximab vedotin plus dacarbazine (DTIC) 104,105 ; VEPEMB (vinblastine, cyclophosphamide, prednisolone, procarbazine, etoposide, mitoxantrone, and bleomycin) 106,107 ; BACOPP (bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) 97 ; and PVAG (prednisone, vinblastine, doxorubicin, and gemcitabine). 108 NCCN Recommendations for Older Adults (Age .60 Years) With CHL The regimens listed subsequently should be considered in older patients to lessen or minimize toxicity (see HODG-F 1 of 2, page 768).…”

“…ABVD, brentuximab vedotin lead in followed by AVD and brentuximab vedotin maintenance, brentuximab vedotin plus DTIC, CHOP, PVAG, and VEPEMB with or without ISRT are included as primary treatment options for elderly patients with stage I-II unfavorable or stage III-IV disease. 45,[102][103][104][105][106][107][108] For the ABVD regimen, a PET scan follows treatment with 2 cycles of ABVD. Bleomycin may be omitted from ABVD.…”

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

“…Brentuximab vedotin has also been assessed as monotherapy and in combination with bendamustine, dacarbazine or nivolumab. 15,17,25,26 Importantly, patients enrolled in this study were ineligible for frontline conventional chemotherapy combinations (via investigator's judgement). Initial assessment of brentuximab vedotin monotherapy demonstrated promising efficacy with 92% of patients (median age 78 years) achieving an ORR (CR: 73%).…”